NCT04137900: Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies

NCT04137900
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received at least one line of therapy for advanced or metastatic disease
Exclusions: Patients with symptomatic, unstable, or untreated CNS & leptomeningeal metastases that require treatment – see trial for details, Patients with prior exposure to anti-BTLA or anti-HVEM antibodies
https://ClinicalTrials.gov/show/NCT04137900

Comments are closed.

Up ↑